Last reviewed · How we verify
cabozantinib and nivolumab
cabozantinib and nivolumab is a Small molecule drug developed by Centre Francois Baclesse. It is currently FDA-approved.
At a glance
| Generic name | cabozantinib and nivolumab |
|---|---|
| Sponsor | Centre Francois Baclesse |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study (PHASE2)
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (PHASE3)
- Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (PHASE2)
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (PHASE2)
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (PHASE2)
- Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (PHASE2)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cabozantinib and nivolumab CI brief — competitive landscape report
- cabozantinib and nivolumab updates RSS · CI watch RSS
- Centre Francois Baclesse portfolio CI
Frequently asked questions about cabozantinib and nivolumab
What is cabozantinib and nivolumab?
cabozantinib and nivolumab is a Small molecule drug developed by Centre Francois Baclesse.
Who makes cabozantinib and nivolumab?
cabozantinib and nivolumab is developed and marketed by Centre Francois Baclesse (see full Centre Francois Baclesse pipeline at /company/centre-francois-baclesse).
What development phase is cabozantinib and nivolumab in?
cabozantinib and nivolumab is FDA-approved (marketed).
Related
- Manufacturer: Centre Francois Baclesse — full pipeline
- Compare: cabozantinib and nivolumab vs similar drugs
- Pricing: cabozantinib and nivolumab cost, discount & access